Sheikh M Salman, Kashani Kianoush B
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Eur J Intern Med. 2025 Apr;134:17-24. doi: 10.1016/j.ejim.2025.01.015. Epub 2025 Jan 31.
Accurate assessment of kidney function is essential for diagnosing and managing chronic kidney disease (CKD) and acute kidney injury (AKI), adjusting drug dosages, and predicting clinical outcomes. Despite its ubiquitous use, serum creatinine has significant limitations, necessitating the exploration of alternative and complementary biomarkers and technologies. This review revisits the benefits and limitations of serum creatinine, explores other kidney function biomarkers such as Cystatin C and ProEnkephalin, and examines traditional gold-standard techniques, including creatinine clearance, radioisotopes, and inulin clearance. Furthermore, it highlights innovations in real-time glomerular filtration rate (GFR) measurement, such as transdermal monitoring using MB-102 and dual fluorescent tracers. We conclude with a discussion on the development, validation, and clinical integration of these advancements, which may redefine renal function assessment in the years to come.
准确评估肾功能对于慢性肾脏病(CKD)和急性肾损伤(AKI)的诊断及管理、调整药物剂量以及预测临床结局至关重要。尽管血清肌酐被广泛使用,但其存在显著局限性,因此有必要探索其他替代和补充生物标志物及技术。本综述重新审视血清肌酐的益处和局限性,探索其他肾功能生物标志物,如胱抑素C和前脑啡肽,并研究传统的金标准技术,包括肌酐清除率、放射性同位素和菊粉清除率。此外,还强调了实时肾小球滤过率(GFR)测量方面的创新,如使用MB - 102和双荧光示踪剂的经皮监测。我们最后讨论这些进展的开发、验证和临床整合,这些进展可能在未来几年重新定义肾功能评估。